An American Thoracic Society/National Heart, Lung, and Blood Institute Workshop Report: Addressing Respiratory Health Equality in the United States

Juan C. Celedón, Esteban G. Burchard, Dean Schraufnagel, Carlos Castillo-Salgado, Marc Schenker, John Balmes, Enid Neptune, Kristin J. Cummings, Fernando Holguin, Kristin A. Riekert, Juan P. Wisnivesky, Joe G. N. Garcia, Jesse Roman, Rick Kittles, Victor E. Ortega, Susan Redline, Rasika Mathias, Al Thomas, Jonathan Samet, and Jean G. Ford; on behalf of the American Thoracic Society and the National Heart, Lung, and Blood Institute

THIS OFFICIAL WORKSHOP REPORT OF THE AMERICAN THORACIC SOCIETY (ATS) AND THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) WAS APPROVED BY THE ATS, March 2017, AND BY THE NHLBI, OCTOBER 2016

Abstract

Health disparities related to race, ethnicity, and socioeconomic status persist and are commonly encountered by practitioners of pediatric and adult pulmonary, critical care, and sleep medicine in the United States. To address such disparities and thus progress toward equality in respiratory health, the American Thoracic Society and the National Heart, Lung, and Blood Institute convened a workshop in May of 2015. The workshop participants addressed health disparities by focusing on six topics, each of which concluded with a panel discussion that proposed recommendations for research on racial, ethnic, and socioeconomic disparities in pulmonary, critical care, and sleep medicine. Such recommendations address best practices to advance research on respiratory health disparities (e.g., characterize broad ethnic groups into subgroups known to differ with regard to a disease of

interest), risk factors for respiratory health disparities (e.g., study the impact of new tobacco or nicotine products on respiratory diseases in minority populations), addressing equity in access to healthcare and quality of care (e.g., conduct longitudinal studies of the impact of the Affordable Care Act on respiratory and sleep disorders), the impact of personalized medicine on disparities research (e.g., implement large studies of pharmacogenetics in minority populations), improving design and methodology for research studies in respiratory health disparities (e.g., use study designs that reduce participants' burden and foster trust by engaging participants as decision-makers), and achieving equity in the pulmonary, critical care, and sleep medicine workforce (e.g., develop and maintain robust mentoring programs for junior faculty, including local and external mentors). Addressing these research needs should advance efforts to reduce, and potentially eliminate, respiratory, sleep, and critical care disparities in the United States.

ORCID ID: 0000-0002-6139-5320 (J.C.C.).

The findings and conclusions in this report are those of the authors, and do not necessarily represent the views of the National Institute for Occupational Safety and Health or the National Institutes of Health.

Correspondence and requests for reprints should be addressed to Juan C. Celedón, M.D., Dr.P.H., Division of Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, 4401 Penn Avenue, Pittsburgh, PA 15224. E-mail: juan.celedon@chp.edu

Ann Am Thorac Soc Vol 14, No 5, pp 814–826, May 2017

Copyright © 2017 by the American Thoracic Society

DOI: 10.1513/AnnalsATS.201702-167WS

Internet address: www.atsjournals.org

Contents

Conceptual Framework

Workshop Agenda

Best Practices to Advance

Research on Respiratory

Health Disparities

Recommendations

Risk Factors for Respiratory

Health Disparities

Recommendations

Addressing Equity in Access

to Healthcare and Quality

of Care

Recommendations

The Impact of Personalized

Medicine on Disparities

Research

Recommendations

Improving Design and

Methodology for Research

Studies of Health Disparities

Recommendations

Achieving Equity in the

Pulmonary, Critical Care, and

Sleep Medicine Workforce

Recommendations

Conclusions and Future Directions

Health disparities can be defined as significant differences in healthcare or outcomes across groups of people who have experienced greater obstacles to health based on their: racial or ethnic group; socioeconomic status (SES); religion; sex; age; occupation; mental health; cognitive or physical disability; sexual orientation; or other characteristics historically linked to discrimination or exclusion. Such disparities explain why the approximate 9-year gain in average life expectancy in the U.S. population over the last four decades has not equally benefited all Americans (1).

Respiratory health equality, the attainment of the highest level of respiratory health for all people, is an ideal and an ultimate goal of the American Thoracic Society (ATS) and the National Heart, Lung, and Blood Institute (NHLBI). This goal is not only morally imperative, but also cost effective, as one study estimated that health equality could have saved at least 1 trillion dollars in direct and indirect healthcare costs from 2003 to 2006 (2). Moreover, efforts to attain health equality (e.g., in influenza vaccination rates [3]) can ultimately benefit all members of our society.

Because achieving equality in respiratory health entails the elimination of health disparities in diseases commonly found in pediatric and adult pulmonary, critical care, and sleep medicine (heretofore referred to as “respiratory health disparities,” for ease of exposition), a necessary step

toward equality is to identify and address the causes of such disparities (4).

Both the ATS and the NHLBI recognize the value of bringing together a diverse group of investigators to develop a consensus on research needs in respiratory health disparities, with an emphasis on racial, ethnic, and socioeconomic disparities. To encourage and facilitate state-of-the-art research on such disparities, the ATS and the NHLBI held a workshop focused on the topic on May 16, 2015.

Conceptual Framework

Respiratory health disparities can result from differences across demographic groups at any stage of the causal pathway leading to disease (Figure 1). Within this causal framework, “upstream” factors are “root causes” of an individual’s exposures to environmental risk factors for respiratory diseases. For example, racism or low SES can influence the neighborhood where a family lives. In turn, area of residence determines indoor and outdoor air quality, which can impact the development or severity of asthma (5, 6).

Environmental exposures and behavioral patterns often differ across demographic groups defined by race/ethnicity or SES, leading to most respiratory health disparities. Major risk factors for such disparities include tobacco use, air pollution, occupational hazards, and obesity (4). Racial

or ethnic groups also have different frequencies for alleles that affect the respiratory system (e.g., sickle cell disease) or are associated with sleep apnea, interact with environmental exposures in causing respiratory disease (e.g., tobacco use and severe α_1 -antitrypsin deficiency in chronic obstructive pulmonary disease [COPD]), or affect response to treatment (e.g., inhaled β_2 -agonists in asthma), all of which have implications for personalized medicine (7–9).

Racial, ethnic, and socioeconomic inequities in healthcare access can cause or worsen respiratory health disparities. Policies aimed to increase healthcare access have shown early potential to reduce health disparities, including those for outcomes in critically ill patients (10–13). However, health insurance does not address other barriers to care, including low health literacy, hurdles to adherence to treatment or adoption of healthy behaviors, and a profound shortage of physicians belonging to underrepresented minority (URM) groups (African Americans, Hispanics, Native Americans or Alaska natives, Hawaiian and Pacific Islanders), who were recently estimated to provide healthcare to 53.5% of minority populations (14).

Workshop Agenda

The workshop participants focused on six topics, each of which concluded with

Figure 1. Causal framework for respiratory diseases. Group differences at any stage in this pathway can lead to respiratory health disparities. Reprinted by permission from Reference 4.

Table 1. Key recommendations for research on racial, ethnic, and socioeconomic disparities in pulmonary, critical care, and sleep medicine

Research Need	Recommendations	Examples	Author, Year (Reference No.)
General guidelines for assessment of race and ethnicity	<p>Characterize broad ethnic groups into subgroups known to differ or potentially differ with regard to the disease of interest</p> <p>Consider measuring genetic ancestry in racially admixed populations, using AIMs</p>	<p>Divide Hispanics into major subgroups according to self-reported place of origin (e.g. Mexican Americans, Puerto Ricans, Cuban Americans, Dominicans)</p> <p>Assess continental or subcontinental ancestry (e.g., African, Native American, and European) in studies of lung function or obstructive airway diseases in African Americans and Hispanics, using AIMs</p> <p>Use of the McArthur sociodemographic questionnaire, which captures data on resources, prestige, and perceived social status within the community</p>	<p>Rosser and colleagues, 2014 (17)</p> <p>Kumar and colleagues, 2010 (18)</p> <p>Bruse and colleagues, 2011 (19)</p> <p>Chen and colleagues, 2014 (20)</p> <p>Pino-Yanes and colleagues, 2015 (21)</p>
General guidelines for assessment of social and economic status	<p>Assess both social and economic status (at the individual, family and community levels) using validated instruments, while also measuring chronic stressors (with the extent of assessment determined by the primary research focus)</p>	<p>Use of the McArthur sociodemographic questionnaire, which captures data on resources, prestige, and perceived social status within the community</p>	<p>www.macses.ucsf.edu/research/psychosocial/subjective.php</p>
Examining acculturation in studies of migrant populations	<p>Capture basic measures of acculturation in all studies of migrant populations</p> <p>Use comprehensive measures of acculturation for in-depth studies</p>	<p>Capture socioeconomic indicators at the community level (e.g. census-track poverty, violence rates, access to healthy foods)</p> <p>Always include place of birth, place of origin, self-reported race/ethnicity, duration of residence in the adoptive country, and fluency in English</p> <p>BAS, AHIMSA</p>	<p>Chen and colleagues, 2013 (24)</p> <p>Ramratham and colleagues, 2015 (25)</p> <p>Vangeepuram and colleagues, 2012 (26)</p>
Characterization of modifiers of the effects of pollution on respiratory health	<p>Estimate the effect of interactions between pollution and other risk factors on respiratory health disparities</p> <p>Create models integrating tobacco exposure throughout life stages and addiction risk</p>	<p>Psychosocial stress</p> <p>Indoor pollutants</p> <p>Extrinsic neighborhood factors</p> <p>Longitudinal birth cohort studies with biomarkers of both exposure to tobacco smoke and susceptibility to addiction</p>	<p>Sundquist and colleagues, 1999 (32)</p> <p>Eldeirawi and colleagues, 2005 (34)</p> <p>Holguin and colleagues, 2005 (35)</p> <p>Marin and Gamba, 1996 (109)</p> <p>Unger and colleagues, 2002 (110)</p>
Better knowledge of the biologic/social basis of nicotine addiction and susceptibility to the effects of tobacco use	<p>Study the impact of e-cigarettes, hookah or new tobacco products on respiratory diseases in underserved populations</p>	<p>Longitudinal studies of adolescents and young adults</p>	<p>Clougherty and colleagues, 2007 (37)</p> <p>Chiu and colleagues, 2013 (39)</p> <p>McCormack and colleagues, 2015 (40)</p> <p>Rydell and colleagues, 2016 (111)</p>
Understanding how new modalities of tobacco or nicotine use affect the respiratory health of minorities and the poor	<p>Incorporate basic measures of occupation and the workplace in all studies of minorities of working age, with use of more in-depth tools in studies focusing on occupation</p>	<p>Current and former employment status, number of hours worked, job type (using standard classifications)</p>	<p>Rath and colleagues, 2016 (112)</p> <p>Bolund and colleagues, 2015 (113)</p>
Gaining knowledge about interactions between occupational and environmental risk factors on respiratory health disparities	<p>Design and implement longitudinal studies of obesity and respiratory/sleep health, as well as culturally targeted interventions to prevent and treat obesity, in minority populations</p>	<p>Studies of obesity and obstructive sleep apnea within the large HCHS/SOL</p>	<p>Cade and colleagues, 2016 (9)</p> <p>Redline and colleagues 2014 (114)</p>
Improved understanding about the impact of obesity on respiratory and sleep disorders in minority populations			

(Continued)

Table 1. (Continued)

Research Need	Recommendations	Examples	Author, Year (Reference No.)
Measuring the impact of increased healthcare access on respiratory health disparities	Conduct longitudinal studies of the effects of the ACA on diseases encountered in pulmonary, critical care and sleep medicine among URMIs and economically disadvantaged populations	Follow-up studies of the impact of the ACA on smoking cessation, morbidity from asthma, and treatment for lung cancer	Sommers and colleagues, 2015 (11) Sommers and colleagues, 2012 (12) Baicker and colleagues, 2013 (13)
Improve adherence and address low health literacy in minority and economically disadvantaged populations	Develop and test culturally targeted interventions to improve adherence to treatment for pulmonary and sleep diseases in minority and economically disadvantaged populations, incorporating cultural norms and beliefs, and addressing pragmatic barriers	Clinical trials of educational interventions using plain language or teach to goal approaches in low-literacy patients	Sobel and colleagues, 2009 (73) Bailey and colleagues, 2012 (74) Bailey and colleagues, 2014 (75)
Lack of biomarkers required for personalized medicine in minority populations	Design and assess educational interventions and multimedia programs to address low health literacy	CAAPA	Kessler and colleagues, 2016 (96)
	Design and implement large pharmacogenetics studies in URMIs		
	Develop novel statistical methods to leverage both global and local genetic ancestry to increase the statistical power of genome-wide association and sequencing studies of respiratory diseases in URMIs	GALA, EVA-PR	Burchard and colleagues, 2004 (115) Chen and colleagues, 2017 (116)
Removal of barriers for participation of minorities in research studies and clinical trials	Conduct birth cohort studies of URMIs with long-term follow up, in order to develop genetic and epigenetic biomarkers of disease risk and disease severity		
	Identify culturally appropriate recruitment strategies, which consider the needs and interests of the target population	HCHS/SOL	Sorlie and colleagues, 2010 (98) Lavange and colleagues, 2010 (99)
	Use study designs that reduce participants' burden and foster trust by engaging participants as decision makers (e.g., through community-based participatory research and advisory groups)		
	Create training modules for research in respiratory health disparities		
Underrepresentation of minorities in academic (pediatric and adult) pulmonary, critical care, and sleep medicine	Development of pipeline programs in URM communities by academic institutions, establishing academic support and mentoring programs for: middle/high school, undergraduate, and medical students from URM groups	Funding from academic institutions (e.g., scholarships), the NHLBI (e.g., pre-K grants), foundations (e.g., ATS Foundation grants on health disparities) and partnerships (e.g., between the ATS and the AMFDP	Celedón and colleagues, 2014 (4) Duncan and colleagues, 2016 (105) Arbery and colleagues, 2014 (106) Maldonado and colleagues, 2014 (107) Thakur and colleagues, 2014 (108)
	Support of junior URM faculty through new or improved funding mechanisms	Goal and metric-oriented approaches to increase the number of URMIs: (1) at the medical school, residency and divisional levels; and (2) in academic leadership positions	

(Continued)

Table 1. (Continued)

Research Need	Recommendations	Examples	Author, Year (Reference No.)
	Hold institutional efforts to recruit and retain URM faculty accountable, as reflected in decisions on federal research funding Develop and implement robust mentoring programs, including local and external mentors, with at least one URM mentor Include URM in decision-making bodies in the ATS (e.g., assembly and societal committees), the NHLBI (e.g., study sections) and academic institutions (e.g., leadership positions) Consider actions that might be taken based on new evidence when designing research studies	The AMFDP The NIH PRIDE Inclusion of at least one URM in the ATS Board of Directors	
Evidence-based policies to address respiratory health disparities	Formally train researchers in policy translation	Antismoking policies based on the Surgeon's General Report Careful consideration of research-based evidence together with interests of stakeholders affected by new policy	U.S. Department of Health and Human Services, 2014 (41)

Definition of abbreviations: ACA = Affordable Care Act; AHIMSA = Acculturation, Habits, and Interests Multicultural Scale; AIMS = ancestry informative markers; AMFDP = Harold Amos Medical Faculty Development Program; ATS = American Thoracic Society; BAS = Bidimensional Acculturation Scale for Hispanics; CAAPA = Consortium on Asthma among African-ancestry Populations in the Americas; EVA-PR = Epigenetic Variation and Asthma in Puerto Ricans; GALA = Genetics of Asthma in Latino Americans; HCHS/SOL = Hispanic Community and Health Study/Study of Latinos; NHLBI = National Heart, Lung, and Blood Institute; NIH = National Institutes of Health; PRIDE = Program to Increase Diversity among Individuals Engaged in Health-Related Research; URM = underrepresented minority.

a panel discussion that resulted in recommendations for research to address “upstream” and “downstream” causes of disparities in pulmonary, critical care and sleep medicine (summarized in Table 1, which also includes relevant examples). Areas of emphasis included best practices to advance research on respiratory health disparities, risk factors for respiratory health disparities, addressing equity in access to and quality of healthcare, the impact of personalized medicine in disparities research, improving design and methodology for research studies in respiratory health disparities, and achieving equity in the pulmonary, critical care, and sleep medicine workforce. Workshop participants are listed immediately before the reference section.

Best Practices to Advance Research on Respiratory Health Disparities

Whereas race has been characterized by an individual's primary continent of origin and skin color, ethnicity is defined by a shared social, linguistic, and cultural heritage (e.g., African American, Hispanic) (15, 16). Hispanics and African Americans have varying degrees of African, European, and Native American genetic ancestry (17), and such ancestral variability has been shown to influence lung function and risk for obstructive airway diseases in these ethnic groups (18–21). Moreover, Hispanics can be further classified into subgroups by country or region of origin, and such subgroups can differ with regard to risk factors and disease burden. For example, Puerto Ricans and Mexican Americans have markedly variable morbidity and mortality from asthma (17), and smoking patterns differ across various Hispanic groups in the United States (22). Thus, combining subgroups or ignoring racial ancestry can lead to biased results of respiratory research studies in Hispanics and other racially admixed populations.

SES is often assessed using a few indicators of income and educational level. However, there is a need to better characterize social and economic status at the individual and community levels. For example, positive social factors, such as community resiliency and cohesiveness, may mitigate the negative effects of low income (23), including detrimental environmental exposures (e.g., mobilization against advertising of tobacco products). Conversely, URM and economically

disadvantaged persons may often be exposed to chronic stressors, such as racism, perceived discrimination, violence, and crime, which have been implicated in worse asthma outcomes (24–28), sleep disorders (29), and inadequate access to high-quality healthcare (30).

Acculturation is the process of cultural exchange by which immigrants modify their attitudes, beliefs, cultural norms, values, or behaviors as a result of interactions with a different culture (31). Acculturation can modify the effect of race/ethnicity or SES on respiratory health—largely by affecting environmental exposures—and is thus an important target for implementation research. The links of acculturation with environmental risk factors and respiratory health disparities may vary by birthplace, country of origin, and years of residence in an adoptive country. For example, a study of 1,000 women of Mexican descent showed that birth in the United States, years lived in the United States, and acculturation were each significantly associated with higher prevalence of cigarette smoking (32). A link between acculturation and smoking has been reported in other studies of female, but not male, Hispanic and Asian immigrants (22, 33). Similar to findings for smoking, birth in the United States has been associated with asthma among Mexican Americans (34, 35).

Recommendations

- Characterize broad ethnic groups into subgroups known to differ or potentially differ with regard to the disease of interest.
- Consider measuring genetic ancestry in racially admixed populations, using ancestry informative markers.
- Assess both social and economic status (at the individual, family, and community levels) using validated instruments, while also measuring chronic stressors (with the extent of assessment determined by the primary research focus).
- Capture basic measures of acculturation in all studies of migrant populations.
- Use comprehensive measures of acculturation for in-depth studies.

Risk Factors for Respiratory Health Disparities

Cumulative risk refers to the aggregate risk from environmental agents and stressors to

which a population is exposed (36). Risk of adverse outcomes from pollution in asthma or COPD may be further increased by intrinsic (e.g., genetics, sex, and life stage) and extrinsic (e.g., violence, lack of community resources, and lack of access to healthcare) factors, as well as the duration of the exposure. For example, recent evidence suggests that exposures to violence and chronic stress interact with air pollution in causing asthma morbidity (37–39), and that obesity increases susceptibility to the detrimental effects of air pollution on COPD (40). Thus, there is a need to assess the biological impact of interactions between chronic exposure to air pollution and other risk factors on respiratory health in disadvantaged and URM populations.

Disparities in tobacco use and morbidity from tobacco use are due to “upstream” causes (e.g., marketing strategies of tobacco companies), factors contributing to enhanced initiation and reduced cessation rates (e.g., mental health, low education), and factors accelerating the onset or severity of respiratory diseases (e.g., comorbidities, healthcare access) (41). Because factors impacting tobacco use are also community-specific, effective tobacco control policies require customization based on objective data and consideration of the societal levels at which tobacco control measures are needed (41).

The tobacco epidemic has indeed become a series of epidemics, affecting different groups in the population to a varying extent. There are strong gradients of tobacco product use by SES indicators, and across racial and ethnic groups (41). These differences relate primarily to industry marketing (e.g., targeting menthol cigarettes toward the African American community). Among some URM, smoking tends to be lower than in non-Hispanic white individuals (e.g., some Hispanic populations), but higher in others (e.g., many Native American tribes). Given the impact of smoking on morbidity and mortality, differences in smoking patterns and the cultural correlates of smoking are relevant to prevention of initiation, promotion of cessation, and lung cancer screening. For example, a randomized, controlled trial of proactive-care smoking cessation among U.S. veterans of war found higher rates of smoking abstinence in African American than in white individuals, a finding that may be explained by access to treatment, higher frequency of light

smoking, and self-motivation to quit among African Americans (42). Thus, there is need for research that is sufficiently rich to provide insights into topics related to smoking (including new nicotine and tobacco products) across population groups.

Occupational risk factors for respiratory disease are unevenly distributed in the population. This disparity occurs across both specific occupational diseases (e.g., pneumoconiosis) and diseases that also have nonoccupational causes (e.g., asthma). Occupational exposures should be assessed in studies of respiratory health disparities, as they may confound relationships between other risk factors and disease. For instance, relationships between poverty and lung disease may reflect respiratory hazards in low-income jobs or reverse causation from loss of income from disabling occupational disease. Moreover, relationships between air pollution and health may reflect the combined effects of occupation and area of residence, given that particulate matter exposures from outdoor air are orders of magnitude lower than those legally permitted in the workplace. Thus, there is a need to improve our understanding of the impact of interactions between environmental and occupational risk factors on respiratory health disparities.

Obesity is a major health problem that disproportionately impacts URM. The prevalence of obesity is substantially higher in Hispanic and African American than in non-Hispanic white individuals. Obesity tracks with other risk factors for health disparities, such as poverty (43). As such, obesity is part of a set of risk factors that can synergistically cause or worsen respiratory and sleep diseases, including asthma (44) and obstructive sleep apnea (45). However, the extent to which obesity explains why URM have a greater burden of respiratory or sleep disorders remains to be characterized. In particular, few clinical trials of weight loss management or bariatric surgery have included adequate numbers of URM. Moreover, there is limited evidence to support culturally targeted interventions to promote respiratory and sleep health through the prevention and treatment of obesity.

Recommendations

- Estimate the effect of interactions between air pollution and other risk factors on respiratory health disparities.

- Create models integrating tobacco exposure throughout life stages and addiction risk.
- Study the impact of e-cigarettes, hookah, or new tobacco products on respiratory diseases in underserved populations.
- Incorporate basic measures of occupation and the workplace in all studies of minorities of working age, with use of more in-depth tools in studies focused on occupation.
- Design and implement longitudinal studies of obesity and respiratory/sleep health, as well as culturally targeted interventions to prevent and treat obesity, in minority populations.

Addressing Equity in Access to Healthcare and Quality of Care

Lack of health insurance is a major barrier to healthcare access and a cause of worse outcomes for respiratory diseases in URM. Uninsured individuals have higher rates of lung cancer, present with more advanced disease, and have higher mortality from lung cancer (46). Similarly, uninsured patients who are critically ill are less likely to receive common critical care procedures and have higher mortality rates (10).

The Affordable Care Act (ACA) of 2010 has significantly decreased the percentage of Americans without health insurance. Early within-state evaluations suggest that insurance expansion may increase the use of preventive services, improve health outcomes, and reduce mortality, especially among low-income and minority populations (11–13). Twenty states, however, have declined, thus far, to enact the Medicaid expansion provision of the ACA, even though some of those states have substantial URM populations (47).

Medical insurance does not guarantee access to high-quality care. Low SES is associated with higher odds of being denied acceptance for lung transplantation, even after adjusting for disease factors (48). Publicly insured low-income and URM children continue to receive poorer healthcare, with worsening disparities for diseases, such as asthma (49). Indeed, low-income and uninsured or publicly insured children experience longer wait times to see specialists, and report less patient-centered care (49, 50). Patients with occupational lung disease also face barriers to healthcare access, as many physicians

do not accept workers' compensation insurance (51).

Even when prescribed, low adherence to therapies for pulmonary and sleep diseases is common, particularly among African American, Hispanic, and publicly insured and low-income people (52–56). Moreover, risk factors for nonadherence to treatment differ by race/ethnicity and SES. For example, URMs with asthma are more likely to have negative beliefs about inhaled corticosteroids and to believe that God determines disease control; such beliefs may mediate the association between race/ethnicity and adherence to treatment (57, 58).

In spite of substantial evidence of barriers to adherence, few adherence intervention trials have been conducted for respiratory or sleep disorders. Although knowledge and better device skills are positively associated with adherence in asthma, simple interventions that provide education and technique training, and/or simplify regimens, do not reliably lead to improved adherence, especially in URMs (59, 60). Motivational enhancement interventions have been shown to improve adherence to continuous positive airway pressure, but these strategies have not been tested in URMs (61). Shared decision-making, setting appropriate expectations for treatment efficacy, and providing reminders may improve adherence with therapies for asthma and sleep apnea (62–66), but these interventions have not been specifically evaluated in URMs.

Health literacy, the "degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions," is usually assessed by testing reading and numeracy skills (67). Adults with low health literacy have poorer healthcare access, and greater morbidity and mortality, than those with adequate health literacy (68, 69). For example, children with asthma whose parents have low literacy are at risk for poor disease control and hospitalizations, and elderly subjects with low literacy are also at risk for asthma morbidity (70, 71). Vulnerable populations, such as URMs, those whose primary language is not English or have low SES, and elderly patients are more likely to lack health literacy skills, and thus not accomplish health-related tasks (70).

Nonadherence to medications or self-management behaviors is one mechanism

through which low health literacy may lead to poor outcomes in pulmonary and sleep diseases (72). Several interventions based on prescription packaging via standardized drug labels, educational interventions using plain language and teach-to-goal or teach-back approaches, and multimedia programs have been proposed to address the needs of patients with low literacy (73–75). However, robust evidence regarding their effectiveness in addressing respiratory health disparities is limited.

Recommendations

- Conduct longitudinal studies of the impact of the ACA on diseases encountered in pulmonary, critical care, and sleep medicine among URMs and economically disadvantaged populations.
- Develop and test culturally targeted interventions to improve adherence to treatment for pulmonary and sleep diseases in minority and economically disadvantaged populations, incorporating cultural norms, values, and beliefs, and addressing pragmatic barriers.
- Design and assess educational interventions and multimedia programs to address low health literacy.

The Impact of Personalized Medicine on Disparities Research

Precision or personalized medicine is a model for healthcare that uses individual patient characteristics, including predictive biomarkers, such as genetic and epigenetic markers, to determine the optimal treatment for an individual (76). This approach is expected to improve clinical practice through risk assessment for risk modification and tailored therapeutic interventions (77). Personalized medicine is expected to improve patient outcomes, but remains expensive and not readily accessible.

A growing field in personalized medicine research is pharmacogenetics, which analyzes gene-by-drug interactions on treatment response. Much has been learned about pharmacogenetics in respiratory diseases, such as lung cancer (78) and asthma (79). Most pharmacogenetics studies of asthma have focused on genes within the β_2 -adrenergic receptor, glucocorticoid, and leukotriene pathways (80–84).

Inclusion of multiethnic populations in pharmacogenetics studies will be critical to account for the diverse genomes of modern populations. Recently admixed populations have varying proportions of different ancestries within their genomes, due to recent gene flow between diverse populations. As a consequence, genetic variants have varying allele frequencies between different ethnic groups (8, 85, 86), which may lead to ethnic-specific differences in treatment response (8). In fact, differential responsiveness to long-acting inhaled β_2 -agonists has been observed comparing non-Hispanic white and African American individuals (82), including increased risk for life-threatening exacerbations and treatment failures in African Americans in some (7, 87), but not all (88), studies. Moreover, rare variants in the gene for the β_2 -adrenergic receptor (*ADRB2*) have been implicated in ethnic-specific response to short- and long-acting inhaled β_2 -agonists (84, 89), emphasizing the importance of evaluating ethnically diverse populations to identify novel determinants of therapeutic response.

“Global” (genome-wide) genetic ancestry has been shown to influence lung function and respiratory diseases (*see* previous text here), and thus assessing such ancestry in racially admixed populations can help epidemiologic, genetic, and pharmacogenetics studies of respiratory health disparities. Moreover, leveraging knowledge of “local” (i.e., chromosome-specific) genetic ancestry through admixture mapping may enhance identification of genes affecting treatment response or health outcomes through genome-wide association or sequencing approaches (90).

Studying genetics and pharmacogenetics in diverse populations is important, but most respiratory diseases are also influenced by social factors and environmental exposures through direct effects, gene-by-environment interactions, and environmentally induced epigenetic changes. Thus, understanding how social and environmental factors interact with genetic variants or affect epigenetic mechanisms may provide clues to molecular pathways, and be informative in assessing determinants of ethnic differences in disease pathogenesis and treatment response (91, 92). For example, DNA methylation changes have been implicated in asthma-related phenotypes (24, 93, 94) and idiopathic pulmonary fibrosis (95). In this context, there is a

critical need for longitudinal studies spanning various life stages (e.g., fetal development, early postnatal life, childhood, and adulthood) in URM subjects.

Recommendations

- Design and implement large pharmacogenetics studies in URM.
- Develop novel statistical methods to leverage both global and local genetic ancestry to increase the statistical power of genome-wide association and sequencing studies of respiratory diseases in URM.
- Conduct birth cohort studies of URM with long-term follow-up to develop genetic and epigenetic biomarkers of disease risk and disease severity.

Improving Design and Methodology for Research Studies of Health Disparities

Engaging minority participants in research studies is critically important to our understanding of common diseases encountered in pulmonary, critical care, and sleep medicine. For example, data from the Consortium on Asthma among African-Ancestry Populations in the Americas (CAAPA) (96, 97) demonstrate both the need for genetics research in URM and the potential for discoveries when conducting such research. Through sequencing over 600 genomes of African ancestry representing the African Diaspora, CAAPA discovered nearly 43.2 million variants, 48% of which are novel (not previously reported in public catalogs of variation including the Single Nucleotide Polymorphism Database (dbSNP)). Most importantly, within the CAAPA genomes, the rate of discovery of these novel alleles is significantly higher on chromosomal regions that are purely African in ancestry as compared with the regions of the genome that are purely European or Native American.

Challenges and opportunities in longitudinal, population-based studies differ from those for genetic research in URM. For example, the Hispanic Community Health Study/Study of Latinos is a longitudinal, population-based cohort study designed to assess the prevalence of common diseases (including some involving the respiratory system and sleep) and identify factors that increase or mitigate risk of such diseases (98, 99). The diverse cohort of 16,000 individuals (ages 17–76 yr) was

recruited in Miami (FL), Chicago (IL), New York (NY), and San Diego (CA) to ensure adequate representation of the major Hispanic subgroups in the United States, including Mexican Americans, Puerto Ricans, Cuban Americans, and South/Central Americans. The study’s success required strong community support at every phase of research. Sites and investigators were experienced in working within the targeted communities, sampling procedures ensured adequate representation of all groups, and instrument selection required cultural sensitivity and validity for all participants. Pilot testing evaluated the study burden to participants and the use of instructional videos. The Hispanic Community Health Study/Study of Latinos exemplifies the need to understand the impact of diversity (in lifestyle, beliefs, behaviors, exposures, ethnicity, place of origin, immigration patterns, and acculturation) on health, including opportunities to discover novel insights into disease pathogenesis, which may ultimately lead to interventions to mitigate health disparities.

More interventional studies are needed to address respiratory health disparities. Similar to observational studies, design of clinical trials in URM should anticipate potential challenges in subject recruitment within a conceptual framework that examines barriers at the level of patients, healthcare providers, and healthcare systems. From the patient perspective, these include barriers to awareness and participation in trials, as well as barriers to acceptance of participation in studies (100). Lack of trust is a frequent barrier to the decision to participate in a trial, and thus the research team’s communication skills (“cultural competence”) are essential to engage and retain URM in research. Increasingly, clinical trials are using patient navigators (nurses or trained laypersons) (101) and Web-based approaches to subject recruitment. Such approaches should be optimized when reaching out to URM, to ensure that their use does not further compromise inclusion of URM in clinical trials.

Recommendations

- Identify culturally appropriate recruitment strategies, which consider the needs and interests of the target population.

- Use study designs that reduce participants' burden and foster trust by engaging participants as decision-makers (e.g., through community-based participatory research and advisory groups).
- Create training modules for research in respiratory health disparities.

Achieving Equity in the Pulmonary, Critical Care, and Sleep Medicine Workforce

In 2010, only 8% of faculty in U.S. medical schools (an engine for healthcare and research) were URMs (102). Moreover, all U.S. scientific research faculty (beyond those in medical schools) include relatively low percentages of URMs, estimated as follows: 4% African American; 4% Hispanic; 0.2% Native American; and 0.1% Hawaiian or Pacific Islander (103). This narrow pool of physicians and scientists partly explains why few URMs are engaged in pulmonary, critical care and sleep medicine research. Of 6,973 ATS members surveyed between 1998 and 2000, 3.9% were Hispanic, 1.5% were African American, and 0.2% were Pacific Islander, Native American or Alaskan Native (104).

Recognizing the need for workforce diversity in academic pulmonary, critical care, and sleep medicine, both the ATS and the NHLBI have further increased their existing efforts to develop new approaches to achieve such diversity (4, 105–108). Participation and retention of URMs in the practice of research on respiratory diseases is influenced by factors encompassing continuous or overlapping stages in professional development, ranging from high school to a position as academic faculty member (105, 107). Thus, there is broad consensus on the need for multipronged approaches to address this issue, involving nongovernmental and governmental funding agencies, academic institutions, professional organizations, such as the Accreditation Council on Graduate Medical Education, professional societies, community organizations, and society at large (4, 105–108).

A recent NHLBI workshop that included early-stage investigators identified key issues facing URM trainees, including lack of exposure to science at a young age, financial barriers (e.g., cost of living), family obligations (e.g., lack of parental leave support, child care issues), restricted

research directions during a postdoctoral fellowship, difficulties in obtaining extramural funding, and lack of external mentors (105). Although some of these issues are also relevant to nonminority trainees, salient issues for URMs include scarce exposure to science during childhood and limited access to external mentors from similar cultural/ethnic backgrounds (105).

Institutional leadership is critical to achieving workforce diversity (107). Academic faculty and academic leaders may not actively oppose diversity efforts, but are often passive or skeptical about the likelihood of success. Skepticism often emanates from the perceived limited pool of qualified applicants, scarcity of resources to support these efforts, and challenges in sustaining improvement in URM student, resident, and faculty diversity. Institutional leadership is highly influential in making progress to achieve workforce diversity. If academic leadership (e.g., the division chief, department chair, and dean) is not willing to make diversity a priority, improvement in academic diversity—at all stages of career development—remains incremental at best. For example, the division chief may not convey an emphasis on diversity to residency or fellowship program directors, and thus diversity metrics may not be monitored in a transparent manner (107). Noninclusion of qualified midcareer and senior URM faculty in key decision-making bodies (e.g., promotion committees, leadership positions) may be an additional obstacle to retention and career advancement of URMs (105).

The Harold Amos Medical Faculty Development Program (AMFDP), funded by the Robert W. Johnson Foundation, is an example of a successful approach to increasing workforce diversity in academic medicine (106). Of the 256 alumni of the AMFDP in 2013, greater than 80% were in academic medicine, with 18 in pulmonary medicine (105). Graduates from the AMFDP include 72 associate professors, 65 professors, 3 National Institutes of Health directors, 4 deans of medical schools, and 10 members of the National Academy of Medicine (106). Consistent with some of what is outlined previously here, the success of the AMFDP has been attributed to several factors: a committed group of advisors, three levels of mentorship (a mentor from the National Advisory

Committee of the AMFDP, a mentor at the trainee's local institution, and an external mentor—with at least one URM mentor), 4-year funding (to support 70% protected time for research effort and a research grant), and an excellent program for career development (106).

Recommendations

- Development of pipeline programs in URM communities by academic institutions, establishing academic support and mentoring programs for: middle/high school, undergraduate, and medical students from URM groups.
- Support of junior URM faculty through new or improved funding mechanisms.
- Hold institutional efforts to recruit and retain URM faculty accountable, as reflected in decisions on federal research funding.
- Develop and implement robust mentoring programs, including local and external mentors, with at least one URM mentor.
- Include URMs in decision-making bodies in the ATS, the NHLBI, and academic institutions.

Conclusions and Future Directions

Eliminating racial, ethnic, and socioeconomic disparities in respiratory health will remain aspirational without a concentrated effort by all stakeholders. Using best practices in health disparities research, considering how research impacts policies affecting minority and economically disadvantaged populations, and developing new approaches to engage and fund trainees and clinical investigators to conduct high-quality research on disparities in pulmonary, critical care, and sleep medicine is essential. In order for all Americans to attain optimal respiratory health, it will be necessary to improve our understanding of the evolving role of personalized medicine and risk factors for respiratory health disparities. The participants at the ATS/NHLBI Workshop on Respiratory Health Equality created a forum to discuss these issues and propose key recommendations. Addressing these recommendations may potentially reduce—and/or eliminate—racial, ethnic, and socioeconomic disparities

in respiratory health in the United States. We hope that this workshop will motivate similar efforts to examine other causes of respiratory health disparities, including sex, sexual orientation, and cognitive and physical disabilities. ■

This Workshop Report was prepared by an *ad hoc* committee of the American Thoracic Society and the National Heart, Lung, and Blood Institute

Members of the committee are as follows:

JUAN C. CELEDÓN, M.D., Dr.P.H. (Chair)
JEAN G. FORD, M.D. (Co-Chair)
JOHN BALMES, M.D.
ESTEBAN G. BURCHARD, M.D., M.P.H.
CARLOS CASTILLO-SALGADO, M.D.
KRISTIN J. CUMMINGS, M.D., M.P.H.
JOE G. N. GARCIA, M.D.
FERNANDO HOLGUIN, M.D., M.P.H.
RICK KITTLES, Ph.D.
RASIKA MATHIAS, Sc.D.
ENID NEPTUNE, M.D.
VICTOR E. ORTEGA, M.D.
SUSAN REDLINE, M.D., M.P.H.
KRISTIN A. RIEKERT, Ph.D.
JESSE ROMAN, M.D.
JONATHAN SAMET, M.D., M.S.
MARC SCHENKER, M.D., M.P.H.
DEAN SCHRAUFNAGEL, M.D.
AL THOMAS, M.D.
JUAN P. WISNIVESKY, M.D., Dr.P.H.

Author disclosures J.B. is a physician member of the California Air Resources Board. K.A.R. served as a consultant for Gilead Sciences Inc. and Genentech; served as an editor for and received royalties from Springer Publishing; served on an advisory committee for Gilead; served as a speaker for Vertex Pharmaceuticals Incorporated. J.P.W. served on an advisory committee for EHE International; received research support from Aventis, Quorum, and Sanofi; served as a consultant for Bristol-Myers Squibb, IMS Health, Merck, and Quintiles. J.R. received research support from Boehringer Ingelheim, Gilead, Fibrogen and Promedior; served as a consultant for Boehringer Ingelheim; and served on a data and safety monitoring board for Genentech. S.R. received research support from Jazz Pharma and Beckman Coulter. J.G.F. served as a consultant for GlaxoSmithKline and is expecting research support from Merck. J.C.C., E.G.B., D.S., C.C.S., M.S., E.N., K.J.C., F.H., J.G.N.G., R.K., V.E.O., R.M., A.T., and J.S. reported no relationships with relevant commercial interests.

Workshop Participants (listed affiliations as of May, 2015): Juan C. Celedón, M.D., Dr.P.H., University of Pittsburgh (Chair); Jean G. Ford, M.D., Brooklyn Hospital Center (Co-Chair); John Balmes, M.D., University of California at San Francisco; Joshua Blatter, M.D., M.P.H., Washington University at Saint Louis; John M. Brehm, M.D., M.P.H., University of Pittsburgh;

Esteban G. Burchard, M.D., M.P.H., University of California at San Francisco; Carlos Castillo-Salgado, M.D., Johns Hopkins University; Kristin J. Cummings, M.D., M.P.H., National Institute of Occupational Safety and Health; Erick Forno, M.D., M.P.H., University of Pittsburgh; Michelle Freemer, M.D., National Heart, Lung, and Blood Institute; Joe G. N. Garcia, M.D., University of Arizona; Fernando Holguin, M.D., M.P.H., University of Pittsburgh; James P. Kiley, Ph.D., National Heart, Lung, and Blood Institute; Rick Kittles, Ph.D., University of Arizona; Alison Lee, M.D., Icahn School of Medicine at Mount Sinai; Sarah Lyon, M.D., University of Pennsylvania; Molly Martin, M.D., University of Illinois at Chicago; Rasika Mathias, Ph.D., Johns Hopkins University; Enid Neptune, M.D., Johns Hopkins University; Sande Okelo, M.D., Ph.D., University of California at Los Angeles; Victor E. Ortega, M.D., Wake Forest University; Susan Redline, M.D., M.P.H., Harvard University; Kristin A. Rieker, Ph.D., Johns Hopkins University; Jesse Roman, M.D., University of Louisville; Christian Rosas-Salazar, M.D., M.P.H., Vanderbilt University; Jonathan Samet, M.D., M.S., University of Southern California; Marc Schenker, M.D., M.P.H., University of California at Davis; Dean Schraufnagel, M.D., University of Illinois at Chicago; Neeta Thakur, M.D., University of California at San Francisco; Al Thomas, M.D., Howard University; Juan P. Wisnivesky, M.D., Dr.P.H., Icahn School of Medicine at Mount Sinai.

References

- Arias E. United States life tables, 2010. *Natl Vital Stat Rep* 2014;63: 1–63.
- LaVeist TA, Gaskin D, Richard P. Estimating the economic burden of racial health inequalities in the United States. *Int J Health Serv* 2011; 41:231–238.
- Lu PJ, O'Halloran A, Williams WW, Lindley MC, Farrall S, Bridges CB. Racial and ethnic disparities in vaccination coverage among adult populations in the U.S. *Am J Prev Med* 2015;49(6 suppl 4): S412–S425.
- Celedón JC, Roman J, Schraufnagel DE, Thomas A, Samet J. Respiratory health equality in the United States: the American Thoracic Society perspective. *Ann Am Thorac Soc* 2014;11: 473–479.
- Breyse PN, Diette GB, Matsui EC, Butz AM, Hansel NN, McCormack MC. Indoor air pollution and asthma in children. *Proc Am Thorac Soc* 2010;7:102–106.
- Guarnieri M, Balmes JR. Outdoor air pollution and asthma. *Lancet* 2014;383:1581–1592.
- Wechsler ME, Castro M, Lehman E, Chinchilli VM, Sutherland ER, Denlinger L, Lazarus SC, Peters SP, Israel E; NHLBI Asthma Clinical Research Network. Impact of race on asthma treatment failures in the asthma clinical research network. *Am J Respir Crit Care Med* 2011;184:1247–1253.
- Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. *J Allergy Clin Immunol* 2014;133:16–26.
- Cade BE, Chen H, Stilp AM, Gleason KJ, Sofer T, Ancoli-Israel S, Arens R, Bell GI, Below JE, Bjornes AC, et al. Genetic associations with obstructive sleep apnea traits in Hispanic/Latino Americans. *Am J Respir Crit Care Med* 2016;194:886–897.
- Lyon SM, Benson NM, Cooke CR, Iwashyna TJ, Ratcliffe SJ, Kahn JM. The effect of insurance status on mortality and procedural use in critically ill patients. *Am J Respir Crit Care Med* 2011;184: 809–815.
- Sommers BD, Long SK, Baicker K. Changes in mortality after Massachusetts health care reform. *Ann Intern Med* 2015;162: 668–669.
- Sommers BD, Baicker K, Epstein AM. Mortality and access to care among adults after state Medicaid expansions. *N Engl J Med* 2012; 367:1025–1034.
- Baicker K, Taubman SL, Allen HL, Bernstein M, Gruber JH, Newhouse JP, Schneider EC, Wright BJ, Zaslavsky AM, Finkelstein AN; Oregon Health Study Group. The Oregon experiment—effects of Medicaid on clinical outcomes. *N Engl J Med* 2013;368:1713–1722.
- Marrast LM, Zallman L, Woolhandler S, Bor DH, McCormick D. Minority physicians' role in the care of underserved patients: diversifying the physician workforce may be key in addressing health disparities. *JAMA Intern Med* 2014;174:289–291.
- Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. *Genome Biol* 2002; 3:comment2007.1–comment2007.12.
- Bamshad M, Wooding S, Salisbury BA, Stephens JC. Deconstructing the relationship between genetics and race. *Nat Rev Genet* 2004;5: 598–609.
- Rosser FJ, Forno E, Cooper PJ, Celedón JC. Asthma in Hispanics: an 8-year update. *Am J Respir Crit Care Med* 2014;189:1316–1327.
- Kumar R, Seibold MA, Aldrich MC, Williams LK, Reiner AP, Colangelo L, Galanter J, Gignoux C, Hu D, Sen S, et al. Genetic ancestry in lung-function predictions. *N Engl J Med* 2010;363:321–330.
- Bruse S, Sood A, Petersen H, Liu Y, Leng S, Celedón JC, Gilliland F, Celli B, Belinsky SA, Tesfaygi Y. New Mexican Hispanic smokers have lower odds of chronic obstructive pulmonary disease and less decline in lung function than non-Hispanic whites. *Am J Respir Crit Care Med* 2011;184:1254–1260.
- Chen W, Brehm JM, Boutaoui N, Soto-Quiros M, Avila L, Celli BR, Bruse S, Tesfaygi Y, Celedón JC. Native American ancestry, lung function, and COPD in Costa Ricans. *Chest* 2014;145:704–710.

- 21 Pino-Yanes M, Thakur N, Gignoux CR, Galanter JM, Roth LA, Eng C, Nishimura KK, Oh SS, Vora H, Huntsman S, *et al*. Genetic ancestry influences asthma susceptibility and lung function among Latinos. *J Allergy Clin Immunol* 2015;135:228–235.
- 22 Kaplan RC, Bangdiwala SI, Barnhart JM, Castañeda SF, Gellman MD, Lee DJ, Pérez-Stable EJ, Talavera GA, Youngblood ME, Giachello AL. Smoking among U.S. Hispanic/Latino adults: the Hispanic community health study/study of Latinos. *Am J Prev Med* 2014;46:496–506.
- 23 Andrews JO, Mueller M, Newman SD, Magwood G, Ahluwalia JS, White K, Tingen MS. The association of individual and neighborhood social cohesion, stressors, and crime on smoking status among African-American women in southeastern US subsidized housing neighborhoods. *J Urban Health* 2014;91:1158–1174.
- 24 Chen W, Boutaoui N, Brehm JM, Han YY, Schmitz C, Cressley A, Acosta-Pérez E, Alvarez M, Colón-Semidey A, Baccarelli AA, *et al*. ADCYAP1R1 and asthma in Puerto Rican children. *Am J Respir Crit Care Med* 2013;187:584–588.
- 25 Ramratnam SK, Han YY, Rosas-Salazar C, Forno E, Brehm JM, Rosser F, Marsland AL, Colón-Semidey A, Alvarez M, Miller GE, *et al*. Exposure to gun violence and asthma among children in Puerto Rico. *Respir Med* 2015;109:975–981.
- 26 Vangeepuram N, Galvez MP, Teitelbaum SL, Brenner B, Wolff MS. The association between parental perception of neighborhood safety and asthma diagnosis in ethnic minority urban children. *J Urban Health* 2012;89:758–768.
- 27 Cohen RT, Celedón JC. Community violence and health disparities in asthma. *J Pediatr* 2016;173:13–15.
- 28 Coogan PF, Yu J, O'Connor GT, Brown TA, Cozier YC, Palmer JR, Rosenberg L. Experiences of racism and the incidence of adult-onset asthma in the Black Women's Health Study. *Chest* 2014;145:480–485.
- 29 Grandner MA, Hale L, Jackson N, Patel NP, Gooneratne NS, Troxel WM. Perceived racial discrimination as an independent predictor of sleep disturbance and daytime fatigue. *Behav Sleep Med* 2012;10:235–249.
- 30 Barnato AE, Berhane Z, Weissfeld LA, Chang CC, Linde-Zwirble WT, Angus DC; Robert Wood Johnson Foundation ICU End-of-Life Peer Group. Racial variation in end-of-life intensive care use: a race or hospital effect? *Health Serv Res* 2006;41:2219–2237.
- 31 Williams CL, Berry JW. Primary prevention of acculturative stress among refugees: application of psychological theory and practice. *Am Psychol* 1991;46:632–641.
- 32 Sundquist J, Winkleby MA. Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988–1994. *Am J Public Health* 1999;89:723–730.
- 33 Reiss K, Lehnhardt J, Razum O. Factors associated with smoking in immigrants from non-western to western countries—what role does acculturation play? A systematic review. *Tob Induc Dis* 2015;13:11.
- 34 Eldeirawi K, McConnell R, Freels S, Persky VW. Associations of place of birth with asthma and wheezing in Mexican American children. *J Allergy Clin Immunol* 2005;116:42–48.
- 35 Holguin F, Mannino DM, Antó J, Mott J, Ford ES, Teague WG, Redd SC, Romieu I. Country of birth as a risk factor for asthma among Mexican Americans. *Am J Respir Crit Care Med* 2005;171:103–108.
- 36 U.S. Environmental Protection Agency. Framework for cumulative risk assessment. Washington, D.C.: U.S. EPA; 2016. EPA/630/P-02/001F May 2003.
- 37 Clougherty JE, Levy JI, Kubzansky LD, Ryan PB, Suglia SF, Canner MJ, Wright RJ. Synergistic effects of traffic-related air pollution and exposure to violence on urban asthma etiology. *Environ Health Perspect* 2007;115:1140–1146.
- 38 Clougherty JE, Rossi CA, Lawrence J, Long MS, Diaz EA, Lim RH, McEwen B, Koutrakis P, Godleski JJ. Chronic social stress and susceptibility to concentrated ambient fine particles in rats. *Environ Health Perspect* 2010;118:769–775.
- 39 Chiu YH, Coull BA, Sternthal MJ, Kloog I, Schwartz J, Cohen S, Wright RJ. Effects of prenatal community violence and ambient air pollution on childhood wheeze in an urban population. *J Allergy Clin Immunol* 2014;133:713–22.e4.
- 40 McCormack MC, Belli AJ, Kaji DA, Matsui EC, Brigham EP, Peng RD, Sellers C, Williams DL, Diette GB, Breyse PN, *et al*. Obesity as a susceptibility factor to indoor particulate matter health effects in COPD. *Eur Respir J* 2015;45:1248–1257.
- 41 U.S. Department of Health and Human services. The health consequences of smoking- 50 years of progress: a report of the Surgeon General. Atlanta: U.S. DHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
- 42 Burgess DJ, van Ryn M, Noorbaloochi S, Clothier B, Taylor BC, Sherman S, Joseph AM, Fu SS. Smoking cessation among African American and white smokers in the Veterans Affairs health care system. *Am J Public Health* 2014;104:S580–S587.
- 43 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. Hyattsville, MD: National Center for Health Statistics; 2012. NCHS data brief, No. 82.
- 44 Dixon AE, Holguin F, Sood A, Salome CM, Pratley RE, Beuther DA, Celedón JC, Shore SA; American Thoracic Society Ad Hoc Subcommittee on Obesity and Lung Disease. An official American Thoracic Society Workshop report: obesity and asthma. *Proc Am Thorac Soc* 2010;7:325–335.
- 45 Malhotra A, Orr JE, Owens RL. On the cutting edge of obstructive sleep apnoea: where next? *Lancet Respir Med* 2015;3:397–403.
- 46 Slatore CG, Au DH, Gould MK; American Thoracic Society Disparities in Healthcare Group. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. *Am J Respir Crit Care Med* 2010;182:1195–1205.
- 47 Where the states stand on Medicaid expansion. updated 2017 Mar 10; accessed 2017 Mar 21. Available from: <https://www.advisory.com/daily-briefing/resources/primers/medicaidmap>
- 48 Quon BS, Psoter K, Mayer-Hamblett N, Aitken ML, Li CI, Goss CH. Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. *Am J Respir Crit Care Med* 2012;186:1008–1013.
- 49 Dougherty D, Chen X, Gray DT, Simon AE. Child and adolescent health care quality and disparities: are we making progress? *Acad Pediatr* 2014;14:137–148.
- 50 Bisgaier J, Rhodes KV. Auditing access to specialty care for children with public insurance. *N Engl J Med* 2011;364:2324–2333.
- 51 Hing E, Burt CW. Characteristics of office-based physicians and their practices: United States, 2003–04. *Vital Health Stat* 2007;(164):1–34.
- 52 Wu AC, Butler MG, Li L, Fung V, Kharbanda EO, Larkin EK, Vollmer WM, Miroshnik I, Davis RL, Lieu TA, *et al*. Primary adherence to controller medications for asthma is poor. *Ann Am Thorac Soc* 2015;12:161–166.
- 53 Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. *Clin Med Res* 2013;11:54–65.
- 54 Charles MS, Blanchette CM, Silver H, Lavalley D, Dalal AA, Mapel D. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. *Curr Med Res Opin* 2010;26:2421–2429.
- 55 Chang J, Freed GL, Prosser LA, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R. Comparisons of health care utilization outcomes in children with asthma enrolled in private insurance plans versus Medicaid. *J Pediatr Health Care* 2014;28:71–79.
- 56 Billings ME, Auckley D, Benca R, Foldvary-Schaefer N, Iber C, Redline S, Rosen CL, Zee P, Kapur VK. Race and residential socioeconomic status as predictors of CPAP adherence. *Sleep* 2011;34:1653–1658.
- 57 Le TT, Bilderback A, Bender B, Wamboldt FS, Turner CF, Rand CS, Bartlett SJ. Do asthma medication beliefs mediate the relationship between minority status and adherence to therapy? *J Asthma* 2008;45:33–37.
- 58 McQuaid EL, Vasquez J, Canino G, Fritz GK, Ortega AN, Colon A, Klein RB, Kopel SJ, Koinis-Mitchell D, Esteban CA, *et al*. Beliefs and barriers to medication use in parents of Latino children with asthma. *Pediatr Pulmonol* 2009;44:892–898.
- 59 Auger KA, Kahn RS, Davis MM, Simmons JM. Pediatric asthma readmission: asthma knowledge is not enough? *J Pediatr* 2015;166:101–108.
- 60 Naar-King S, Lam P, Ellis D, Bruzzese JM, Secord E. Asthma medication device skills in high-risk African American adolescents. *J Asthma* 2013;50:579–582.
- 61 Bakker JP, Wang R, Weng J, Aloia MS, Toth C, Morrical MG, Gleason KJ, Rueschman M, Dorsey C, Patel SR, *et al*. Motivational enhancement for increasing adherence to CPAP: a randomized controlled trial. *Chest* 2016;150:337–345.

- 62 Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, Vollmer WM; Better Outcomes of Asthma Treatment (BOAT) Study Group. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. *Am J Respir Crit Care Med* 2010;181:566–577.
- 63 Clerisme-Beaty EM, Bartlett SJ, Teague WG, Lima J, Irvin CG, Cohen R, Castro M, Wise RA, Rand CS. The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma. *J Allergy Clin Immunol* 2011;127:406–411.
- 64 Petrie KJ, Perry K, Broadbent E, Weinman J. A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. *Br J Health Psychol* 2012;17:74–84.
- 65 Tran N, Coffman JM, Sumino K, Cabana MD. Patient reminder systems and asthma medication adherence: a systematic review. *J Asthma* 2014;51:536–543.
- 66 Aloia MS, Arnedt JT, Strand M, Millman RP, Borrelli B. Motivational enhancement to improve adherence to positive airway pressure in patients with obstructive sleep apnea: a randomized controlled trial. *Sleep* 2013;36:1655–1662.
- 67 Healthy people 2010: health communication. Washington, D.C.: Department of Health and Human Services.
- 68 Baker DW, Gazmararian JA, Sudano J, Patterson M. The association between age and health literacy among elderly persons. *J Gerontol B Psychol Sci Soc Sci* 2000;55:S368–S374.
- 69 Apter AJ, Cheng J, Small D, Bennett IM, Albert C, Fein DG, George M, Van Horne S. Asthma numeracy skill and health literacy. *J Asthma* 2006;43:705–710.
- 70 Rosas-Salazar C, Apter AJ, Canino G, Celedón JC. Health literacy and asthma. *J Allergy Clin Immunol* 2012;129:935–942.
- 71 Rosas-Salazar C, Ramratnam SK, Brehm JM, Han YY, Acosta-Pérez E, Alvarez M, Colón-Semidey A, Canino G, Apter AJ, Celedón JC. Parental numeracy and asthma exacerbations in Puerto Rican children. *Chest* 2013;144:92–98.
- 72 Apter AJ, Wan F, Reisine S, Bender B, Rand C, Bogen DK, Bennett IM, Bryant-Stephens T, Roy J, Gonzalez R, et al. The association of health literacy with adherence and outcomes in moderate-severe asthma. *J Allergy Clin Immunol* 2013;132:321–327.
- 73 Sobel RM, Paasche-Orlow MK, Waite KR, Rittner SS, Wilson EA, Wolf MS. Asthma 1-2-3: a low literacy multimedia tool to educate African American adults about asthma. *J Community Health* 2009;34:321–327.
- 74 Bailey SC, Sarkar U, Chen AH, Schillinger D, Wolf MS. Evaluation of language concordant, patient-centered drug label instructions. *J Gen Intern Med* 2012;27:1707–1713.
- 75 Bailey SC, Wolf MS, Lopez A, Russell A, Chen AH, Schillinger D, Moy G, Sarkar U. Expanding the universal medication schedule: a patient-centred approach. *BMJ Open* 2014;4:e003699.
- 76 Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015;372:793–795.
- 77 Chan IS, Ginsburg GS. Personalized medicine: progress and promise. *Annu Rev Genomics Hum Genet* 2011;12:217–244.
- 78 Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. *Lancet* 2017;389:299–311.
- 79 Meyers DA, Bleecker ER, Holloway JW, Holgate ST. Asthma genetics and personalised medicine. *Lancet Respir Med* 2014;2:405–415.
- 80 Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, Torres A, Gorman JD, Salari K, Rodriguez-Santana JR, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. *Am J Respir Crit Care Med* 2005;171:563–570.
- 81 Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, Lange C, Lazarus R, Sylvia J, Klanderman B, et al. Genomewide association between GLCC1 and response to glucocorticoid therapy in asthma. *N Engl J Med* 2011;365:1173–1183.
- 82 Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet* 2004;364:1505–1512.
- 83 Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, et al.; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. *Lancet* 2009;374:1754–1764.
- 84 Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, Castro M, Chardon D, Erzurum SC, Israel E, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study. *Lancet Respir Med* 2014;2:204–213.
- 85 Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA; 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012;491:56–65.
- 86 Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* 2015;526:68–74.
- 87 Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, Group SS; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129:15–26.
- 88 Peters SP, Bleecker ER, Canonica GW, Park YB, Ramirez R, Hollis S, Fjallbrant H, Jorup C, Martin UJ. Serious asthma events with budesonide plus formoterol vs. budesonide alone. *N Engl J Med* 2016;375:850–860.
- 89 Drake KA, Torgerson DG, Gignoux CR, Galanter JM, Roth LA, Huntsman S, Eng C, Oh SS, Yee SW, Lin L, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. *J Allergy Clin Immunol* 2014;133:370–378.
- 90 Pino-Yanes M, Gignoux CR, Galanter JM, Levin AM, Campbell CD, Eng C, Huntsman S, Nishimura KK, Gourraud PA, Mohajeri K, et al. Genome-wide association study and admixture mapping reveal new loci associated with total IgE levels in Latinos. *J Allergy Clin Immunol* 2015;135:1502–1510.
- 91 Cornelis MC, Agrawal A, Cole JW, Hansel NN, Barnes KC, Beaty TH, Bennett SN, Bierut LJ, Boerwinkle E, Doherty KF, et al.; GENEVA Consortium. The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. *Genet Epidemiol* 2010;34:364–372.
- 92 Brehm JM, Ramratnam SK, Tse SM, Croteau-Chonka DC, Pino-Yanes M, Rosas-Salazar C, Litonjua AA, Raby BA, Boutaoui N, Han YY, et al. Stress and bronchodilator response in children with asthma. *Am J Respir Crit Care Med* 2015;192:47–56.
- 93 Liang L, Willis-Owen SA, Laprise C, Wong KC, Davies GA, Hudson TJ, Binia A, Hopkin JM, Yang IV, Grundberg E, et al. An epigenome-wide association study of total serum immunoglobulin E concentration. *Nature* 2015;520:670–674.
- 94 Yang IV, Pedersen BS, Liu A, O'Connor GT, Teach SJ, Kattan M, Misiak RT, Gruchalla R, Steinbach SF, Szeftler SJ, et al. DNA methylation and childhood asthma in the inner city. *J Allergy Clin Immunol* 2015;136:69–80.
- 95 Yang IV, Pedersen BS, Rabinovich E, Hennessy CE, Davidson EJ, Murphy E, Guardela BJ, Tedrow JR, Zhang Y, Singh MK, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2014;190:1263–1272.
- 96 Kessler MD, Yerges-Armstrong L, Taub MA, Shetty AC, Maloney K, Jeng LJ, Ruczinski I, Levin AM, Williams LK, Beaty TH, et al.; Consortium on Asthma among African-Ancestry Populations in the Americas (CAAPA). Challenges and disparities in the application of personalized genomic medicine to populations with African ancestry. *Nat Commun* 2016;7:12521.
- 97 Mathias RA, Taub MA, Gignoux CR, Fu W, Musharoff S, O'Connor TD, Vergara C, Torgerson DG, Pino-Yanes M, Shringarpure SS, et al.; CAAPA. A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. *Nat Commun* 2016;7:12522.

- 98 Sorlie PD, Avilés-Santa LM, Wassertheil-Smolter S, Kaplan RC, Daviglius ML, Giachello AL, Schneiderman N, Raji L, Talavera G, Allison M, *et al.* Design and implementation of the Hispanic Community Health Study/Study of Latinos. *Ann Epidemiol* 2010;20: 629–641.
- 99 Lavange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, Liu K, Giachello A, Lee DJ, Ryan J, *et al.* Sample design and cohort selection in the Hispanic Community Health Study/ Study of Latinos. *Ann Epidemiol* 2010;20:642–649.
- 100 Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, Tilburt J, Baffi C, Tanpitukpongse TP, Wilson RF, *et al.* Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. *Cancer* 2008;112:228–242.
- 101 Hedlund N, Risendal BC, Pauls H, Valverde PA, Whitley E, Esparza A, Stiehl E, Calhoun E. Dissemination of patient navigation programs across the United States. *J Public Health Manag Pract* 2014;20: E15–E24.
- 102 Guevara JP, Adanga E, Avakame E, Carthon MB. Minority faculty development programs and underrepresented minority faculty representation at us medical schools. *JAMA* 2013;310:2297–2304.
- 103 Valentine HA, Collins FS. National Institutes of Health addresses the science of diversity. *Proc Natl Acad Sci USA* 2015;112:12240–12242.
- 104 Schnapp LM, Matosian M, Weisman I, Welsh CH. A snapshot of pulmonary medicine at the turn of the century: the American Thoracic Society membership. *Am J Respir Crit Care Med* 2003; 167:1176–1180.
- 105 Duncan GA, Lockett A, Villegas LR, Almodovar S, Gomez JL, Flores SC, Wilkes DS, Tigno XT. National Heart, Lung, and Blood Institute workshop summary: enhancing opportunities for training and retention of a diverse biomedical workforce. *Ann Am Thorac Soc* 2016;13:562–567.
- 106 Ardery NL, Krol DM, Wilkes DS; The Harold Amos Medical Faculty Development Program. Leveraging diversity in American academic medicine: the Harold Amos Medical Faculty Development Program. *Ann Am Thorac Soc* 2014;11:600–602.
- 107 Maldonado ME, Fried ED, DuBose TD, Nelson C, Breida M. The role that graduate medical education must play in ensuring health equity and eliminating health care disparities. *Ann Am Thorac Soc* 2014; 11:603–607.
- 108 Thakur N, McGarry ME, Oh SS, Galanter JM, Finn PW, Burchard EG; ATS Health Equality Committee. The lung corps' approach to reducing health disparities in respiratory disease. *Ann Am Thorac Soc* 2014;11:655–660.
- 109 Marin G, Gamba RJ. A New Measurement of Acculturation for Hispanics: The Bidimensional acculturation scale for Hispanics (BAS). *Hisp J Behavioral Sci* 1996;18:297–316.
- 110 Unger JB, Gallaher P, Shakib P, Ritt-Olson, Palmer PH, Johnson CA. The AHMSA acculturation scale: a new measure of acculturation for adolescents in a multicultural society. *J Early Adolescence* 2002; 22:225–251.
- 111 Rydell M, Granath F, Cnattingius S, Svensson AC, Magnusson C, Galanti MR. Maternal smoking during pregnancy and offspring's tobacco dependence. A study of exposure-discordant sibling pairs. *Drug Alcohol Depend*. 2016;167:23–28.
- 112 Rath JM, Villanti AC, Williams VF, Richardson A, Pearson JL, Vallone DM. Correlates of current menthol cigarette and flavored other tobacco product use among U.S. young adults. *Addict Behav* 2016;62:35–41.
- 113 Bolund ACS, Miller MR, Basinas I, Elholm G, Omland O, Sigsgaard T, Schlünssen V. The effect of occupational farming on lung function development in young adults: a 15-year follow-up study. *Occup Environ Med* 2015;72:707–713.
- 114 Redline S, Sotres-Alvarez D, Loreda J, Hall M, Patel SR, Ramos A, Shah N, Ries A, Arens R, Barnhart J, *et al.* Sleep-disordered breathing in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health Study/Study of Latinos. *Am J Respir Crit Care Med* 2014;189:335–344.
- 115 Burchard EG, Avila PC, Nazario S, Casal J, Torres A, Rodriguez-Santana JR, Toscano M, Sylvia JS, Alioto M, Salazar M, *et al.* Genetics of Asthma in Latino Americans (GALA) Study. Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. *Am J Respir Crit Care Med* 2004;169: 386–392.
- 116 Chen W, Wang T, Pino-Yanes M, Forno E, Liang L, Yan Q, Hu D, Weeks DE, Baccarelli A, Acosta-Perez E, *et al.* An epigenome-wide association study of total serum IgE in Hispanic children. *J Allergy Clin Immunol* (In press).